Alcidion Group Limited (ASX:ALC): What Do FY27 Hospital Contracts Reveal?

Aditi Sarkar

13 November 2026 03:25 PM AEDT

Alcidion Group Limited (ASX:ALC): What Do FY27 Hospital Contracts Reveal?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Alcidion (ASX:ALC) traded at AUD 0.12 on 13 November 2026, up 14.29%.
FY27 contracted Revenue reached AUD 50.0 million at September-end.
Northern Care Alliance expanded its agreement to AUD 7.5 million.
Management reconfirmed FY27 revenue and underlying EBITDA growth guidance.

Alcidion Group Limited supplies healthcare software designed to assist hospitals with patient flow, clinical workflows and access to operational information. On 13 November 2026, Alcidion (ASX:ALC) was trading at AUD 0.12, up 14.29% during the session. The company's October trading update detailed expanded hospital contracts, development of its Miya platform and a higher contracted-revenue position for FY27. Those operational announcements predate the session and should not automatically be treated as the cause of the price movement.

Miya Platform and Hospital Operations

Alcidion (ASX:ALC) operates across Australia, New Zealand and the United Kingdom. Its Miya platform integrates information from hospital systems and supports tools for patient administration, clinical workflow, care coordination and virtual care. The company's offering is directed at healthcare organisations managing patient movement, staffing pressure and administrative demands. Software implementations can include multiple modules and additional sites, creating a distinction between a contracted sale and revenue recognised as delivery obligations are satisfied.

Northern Care Alliance and New Zealand Contracts

The company's October 2026 update described an expanded agreement with Northern Care Alliance NHS Foundation Trust in the United Kingdom. The arrangement has a total contract value of AUD 7.5 million over three years, with Options to extend the term to five years. Alcidion expects approximately AUD 4.5 million of revenue to be recognised in FY27, although delivery timing remains relevant. The agreement includes replacement of an existing ExtraMed patient-flow solution at Salford Royal Hospital and expansion to additional trust sites. In New Zealand, Health NZ MidCentral extended its contract to Whanganui Hospital, increasing the geographic reach of Miya within that customer network.

Contracted Revenue and FY27 Guidance

As of 30 September 2026, Alcidion reported AUD 50.0 million of FY27 contracted revenue from sales and renewals, a 38% increase over the corresponding period. This contracted amount provides visibility but is not equivalent to fully recognised annual revenue. Management reconfirmed guidance for both FY27 revenue and underlying Earnings before interest, tax, Depreciation and Amortisation to exceed FY26 levels. The company has also been integrating the Kyra flow products Business acquired in June 2026, bringing transitional services in-house and working on cost synergies.

Product Development and Capital Management

Alcidion announced Miya Patient Administration, a product intended to support referral, booking, waiting-list and capacity management. Its design draws on existing patient-administration expertise and incorporates real-time integration capabilities. The company separately announced an on-market buy-back covering up to 10% of issued ordinary shares, subject to programme limits and capital-allocation decisions. A proposed ten-for-one share consolidation was also put to shareholders, and subsequent November disclosures reported its approval. Neither action changes the economic performance of hospital software contracts on its own.

Execution Risks and Monitoring Points

Alcidion (ASX:ALC) must implement contracted systems, retain customer relationships and manage integration spending. Public-sector procurement cycles, implementation schedules, software interoperability and security requirements could affect the timing and cost of delivery. The next indicators are conversion of the AUD 50.0 million contracted base into reported revenue, progress on the Northern Care Alliance rollout and the contribution of acquired products. Expansion discussions in Canada and the Middle East remain commercial initiatives rather than confirmed financial outcomes.

Key Insights

Alcidion's FY27 update combines a larger contracted-revenue base with identifiable expansion projects in two established markets. Its product and Acquisition strategy adds integration responsibilities, while the buy-back and consolidation concern capital structure. Financial reporting will clarify recognised revenue, underlying EBITDA and whether implementation remains aligned with management's stated guidance.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.